Acumen Pharmaceuticals has selected Avid Bioservices to provide process development and clinical manufacturing services in support of ACU193, which is being developed for the treatment of Alzheimer’s disease.     ACU193 is a fully humanized IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers, potentially blocking their toxic effects.  Avid and Acumen will immediately commence process development work with the goal of creating a robust, cost-effective and scalable process...